Robert E. Landry - 11 Aug 2025 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Reporting relationship
Director
Issuer ticker
ZYME
Reported as of
11 Aug 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Aug 2025, 20:30:04 UTC
Prior SEC filing
12 Aug 2025
Next SEC filing
12 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Robert E. Landry filed Form 4 for Zymeworks Inc. (ZYME) on 12 Aug 2025.

Key facts

  • This page summarizes Robert E. Landry's Form 4 filing for Zymeworks Inc. (ZYME).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 12 Aug 2025, 20:30.

Change

  • Previous filing in this sequence was filed on 12 Aug 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001585160 Primary reporting owner

Landry Robert E

Relationship
Director
Address
C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Signature
/s/ Daniel Dex, Attorney-in-Fact
Signature date
12 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+62,000
Change %
Price
$0.000000
Shares after
62,000
Date
11 Aug 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
62,000
Exercise price
$12.44
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock options vest in 36 equal monthly installments starting one month after grant date of August 11, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .